Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

Irene Terrenato, Francesca Sperati, Felice Musicco, Anna F. Pozzi, Annunziata di Turi, Mauro Caterino, Elisabetta de Lutio di Castelguidone, Sergio V. Setola, Massimo Bellomi, Carlo E. Neumaier, Laura Conti, Giovanni Cigliana, Roberta Merola, Anna Antenucci, Giulia Orlandi, Antonio Giordano, Maddalena Barba, Stefano Canitano

Research output: Contribution to journalArticle

Abstract

To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation (%Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR %Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms.
Original languageEnglish
Pages (from-to)2572-2580
Number of pages9
JournalJournal of Cellular Physiology
Volume233
Issue number3
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

iopromide
Randomized Controlled Trials
Contrast Media
Neoplasms
Glomerular Filtration Rate
Safety
Pelvis
Abdomen
Arm
Thorax
Tomography
iodixanol

Keywords

  • cancer patients, contrast induced nephropathy, low-osmolar/iso-osmolar contrast medium

Cite this

Terrenato, I., Sperati, F., Musicco, F., Pozzi, A. F., di Turi, A., Caterino, M., ... Canitano, S. (2018). Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. Journal of Cellular Physiology, 233(3), 2572-2580. https://doi.org/10.1002/jcp.26132

Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. / Terrenato, Irene; Sperati, Francesca; Musicco, Felice; Pozzi, Anna F.; di Turi, Annunziata; Caterino, Mauro; de Lutio di Castelguidone, Elisabetta; Setola, Sergio V.; Bellomi, Massimo; Neumaier, Carlo E.; Conti, Laura; Cigliana, Giovanni; Merola, Roberta; Antenucci, Anna; Orlandi, Giulia; Giordano, Antonio; Barba, Maddalena; Canitano, Stefano.

In: Journal of Cellular Physiology, Vol. 233, No. 3, 01.03.2018, p. 2572-2580.

Research output: Contribution to journalArticle

Terrenato, I, Sperati, F, Musicco, F, Pozzi, AF, di Turi, A, Caterino, M, de Lutio di Castelguidone, E, Setola, SV, Bellomi, M, Neumaier, CE, Conti, L, Cigliana, G, Merola, R, Antenucci, A, Orlandi, G, Giordano, A, Barba, M & Canitano, S 2018, 'Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial', Journal of Cellular Physiology, vol. 233, no. 3, pp. 2572-2580. https://doi.org/10.1002/jcp.26132
Terrenato I, Sperati F, Musicco F, Pozzi AF, di Turi A, Caterino M et al. Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. Journal of Cellular Physiology. 2018 Mar 1;233(3):2572-2580. https://doi.org/10.1002/jcp.26132
Terrenato, Irene ; Sperati, Francesca ; Musicco, Felice ; Pozzi, Anna F. ; di Turi, Annunziata ; Caterino, Mauro ; de Lutio di Castelguidone, Elisabetta ; Setola, Sergio V. ; Bellomi, Massimo ; Neumaier, Carlo E. ; Conti, Laura ; Cigliana, Giovanni ; Merola, Roberta ; Antenucci, Anna ; Orlandi, Giulia ; Giordano, Antonio ; Barba, Maddalena ; Canitano, Stefano. / Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial. In: Journal of Cellular Physiology. 2018 ; Vol. 233, No. 3. pp. 2572-2580.
@article{3843e8486723421db0aea5fc49637da4,
title = "Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial",
abstract = "To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation ({\%}Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR {\%}Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms.",
keywords = "cancer patients, contrast induced nephropathy, low-osmolar/iso-osmolar contrast medium",
author = "Irene Terrenato and Francesca Sperati and Felice Musicco and Pozzi, {Anna F.} and {di Turi}, Annunziata and Mauro Caterino and {de Lutio di Castelguidone}, Elisabetta and Setola, {Sergio V.} and Massimo Bellomi and Neumaier, {Carlo E.} and Laura Conti and Giovanni Cigliana and Roberta Merola and Anna Antenucci and Giulia Orlandi and Antonio Giordano and Maddalena Barba and Stefano Canitano",
year = "2018",
month = "3",
day = "1",
doi = "10.1002/jcp.26132",
language = "English",
volume = "233",
pages = "2572--2580",
journal = "Journal of Cellular Physiology",
issn = "1097-4652",
publisher = "Wiley-Liss Inc.",
number = "3",

}

TY - JOUR

T1 - Iodixanol versus iopromide in cancer patients: Evidence from a randomized clinical trial

AU - Terrenato, Irene

AU - Sperati, Francesca

AU - Musicco, Felice

AU - Pozzi, Anna F.

AU - di Turi, Annunziata

AU - Caterino, Mauro

AU - de Lutio di Castelguidone, Elisabetta

AU - Setola, Sergio V.

AU - Bellomi, Massimo

AU - Neumaier, Carlo E.

AU - Conti, Laura

AU - Cigliana, Giovanni

AU - Merola, Roberta

AU - Antenucci, Anna

AU - Orlandi, Giulia

AU - Giordano, Antonio

AU - Barba, Maddalena

AU - Canitano, Stefano

PY - 2018/3/1

Y1 - 2018/3/1

N2 - To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation (%Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR %Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms.

AB - To assess the safety profile of iso-osmolar contrast medium (CM) versus low osmolar CM in cancer patients with an estimated glomerular filtration rate (eGFR) >60 ml/min. In this multicenter, blind trial of patients seeking a chest-abdomen-pelvis contrast enhanced computed tomography (CT) with iodated CM, participants were centrally randomized to iodixanol or iopromide. Contrast induced nephropathy (CIN) at 24 and/or 72 hr were our primary outcomes. We further considered irreversible CIN, average eGFR percentage variation (%Δ), and adverse events (AEs). Overall, 607 patients were enrolled. Among them, 497 eligible patients were randomized to iodixanol (N: 247) or iopromide (N: 250). No differences emerged by descriptive characteristics. Seven and 3 CIN at 24 hr (p = 0.34) and 8 and 2 CIN at 72 hr (p = 0.11) occurred in the iopromide and iodixanol group, respectively. Within the subgroup of individual patients who developed CIN (N: 17), the event rate was higher in the iopromide arm (p = 0.045). No cases of permanent CIN or significant differences in terms of AEs or GFR %Δ were observed. Our results suggest a more favorable safety profile of iodixanol versus iopromide. Adequately sized trials with similar design are warranted to confirm our findings and clarify the underlying biological mechanisms.

KW - cancer patients, contrast induced nephropathy, low-osmolar/iso-osmolar contrast medium

U2 - 10.1002/jcp.26132

DO - 10.1002/jcp.26132

M3 - Article

VL - 233

SP - 2572

EP - 2580

JO - Journal of Cellular Physiology

JF - Journal of Cellular Physiology

SN - 1097-4652

IS - 3

ER -